Abstracts

A Precision Randomized Trial of Hepatitis C Treatment Adherence Support Among 3000 PWID in India

Background: HCV elimination is unlikely without curing people who inject drugs (PWID). Many PWID will need additional support to achieve HCV cure, but resources are limited, particularly in low-and-middle-income countries. A precision approach could improve the efficiency of intervention delivery. The STOP-C trial evaluated whether HCV treatment outcomes could be optimized by tailoring adherence support…

Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch

Background: Preexisting resistance can affect antiretroviral (ARV) efficacy. Circulating HIV-1 variants with drug resistance-associated mutations (RAMs) can be archived in viral reservoirs, where they can persist and re-emerge. Given the dynamic properties of the latent reservoir, detection of these RAMs over time has not been well defined. Methods: Participants from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) switch studies…

Virologic Failure With Cabotegravir-Rilpivirine Injections: A Single-Site Experience

Background: Cabotegravir-rilpivirine (CAB-RPV), the first intramuscular injectable antiretroviral therapy (ART) for people with HIV, is associated with high compliance rates and patient satisfaction. Multiple studies demonstrate low rates of virologic failure (VF) and development of resistance, confirmed by real world analyses. Here we describe our experience with a higher rate of VF at an HIV…

Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations

Background: In 2 phase 3 clinical trials, switching to the 2-drug combination doravirine/islatravir (DOR/ISL) 100/0.75mg was non-inferior to continuing the prior antiretroviral (ART) regimen. This exploratory post-hoc analysis examined the impact of pre-existing resistance-associated mutations (RAMs) on the virologic response to DOR/ISL in these trials, focusing on M184V/I and other RAMs in reverse transcriptase. Methods:…

Molnupiravir vs Favipiravir: An RCT in Outpatients At-Risk for COVID-19 in Thailand

Background: In December 2021, molnupiravir was granted a US FDA’s emergency use authorization for patients with mild-to-moderate COVID-19 at high risk for progression to severe COVID-19 for whom alternative approved or authorized treatment options are not accessible or clinically appropriate. The efficacy of molnupiravir in a vaccinated population predominantly infected with the SARS-CoV-2 Omicron variant…

Phase II Study of Switch to Daily BIC + LEN in Individuals on a Multitablet HIV Treatment Regimen

Background: While single-tablet regimens (STRs) are currently the global standard for HIV treatment, some people with HIV (PWH) take multi-tablet regimens (MTR) due to treatment resistance, intolerance or drug interactions. The combination of bictegravir (BIC), an integrase strand transfer inhibitor, and lenacapavir (LEN), a first-in-class capsid inhibitor, could simplify treatment in virologically suppressed (VS) PWH…

Switching to DTG+3TC vs 3-Drug Regimens in Routine Clinical Care: Long-Term Swedish Data

Background: Swedish HIV treatment guidelines recommend that switching to the 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) for maintaining virologic suppression should be considered in people living with HIV (PLHIV) in routine clinical care. We assessed long-term outcomes of switching to DTG+3TC (vs 3-drug regimens, 3DR) in virologically suppressed individuals in Sweden. Methods: Retrospective data…

Lenacapavir Efficacy in CAPELLA Patients With No Fully Active Agents in Optimized Background Regimen

Background: Lenacapavir (LEN), a long-acting HIV-1 capsid inhibitor, is approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR) in combination with other antiretrovirals (ARVs). LEN is highly potent with no overlapping resistance with other ARVs. In CAPELLA, LEN in combination with an optimized background regimen (OBR) led to…

Antiretroviral Concentrations in Post-Mortem Tissues: Preliminary Results From the Last Gift Program

Background: Antiretroviral therapy (ART) successfully inhibits HIV replication but cannot eradicate the viral reservoir in various anatomic compartments. This is partially due to differential antiretroviral (ARV) drug penetration in different compartments. In humans, ARVs measurement in reservoirs is complicated by technical and ethical obstacles in performing tissue biopsies in vivo. Here we present a map…